Results from a phase 3, multicenter, noninferiority study of ravulizumab (ALXN1210) versus eculizumab (ECU) in adult patients (PTS) with paroxysmal nocturnal hemoglobinuria (PNH) naive to complement inhibitors (CI)

Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/30340

Title:	Results from a phase 3, multicenter, noninferiority study of ravulizumab (ALXN1210) versus eculizumab (ECU) in adult patients (PTS) with paroxysmal nocturnal hemoglobinuria (PNH) naive to complement inhibitors (CI)
Authors:	SCHREZENMEIER, H.; LEE, J. W.; ROTTINGHAUS, S. T.; LEE, Lee L. W.; PESSOA, V.; GUALANDRO, S.; FUEREDER, W.; PTUSHKIN, V.; FONTBRUNE, Sicre F. de; VOLLES, L.; SHAFNER, L.; DAMOKOSH, A. I.; AGUZZI, R.; PRADHAN, R.; ORTIZ, S.; HILL, A.
Citation:	ONCOLOGY RESEARCH AND TREATMENT, v.41, suppl.4, p.332-+, 2018
Appears in Collections:	Comunicações em Eventos - FM/MCM Departamento de Clínica Médica - FM/MCM Comunicações em Eventos - HC/ICHC Instituto Central - HC/ICHC

Files in This Item:

There are no files associated with this item.